Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients

Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients

In the single-arm non-interventional OTILIA study, patients with newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) stage IIIB–IV ovarian cancer received bevacizumab (15 mg/kg every 3 weeks for up to 15 months) and standard carboplatin–paclitaxel. The primary aim was to ass...

Full description

Bibliographic Details
Main Authors: Jalid Sehouli, Alexander Mustea, Guelten Oskay-Özcelik, Maren Keller, Rolf Richter, Oliver Tomé, Hannah Woopen, Ann-Katrin Sommer-Joos, Jacek P. Grabowski, Robert Armbrust, Pauline Wimberger
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
bevacizumab
ovarian cancer
anti-angiogenic
platinum–taxane
chemotherapy
Online Access:https://www.mdpi.com/2072-6694/13/19/4739

Internet

https://www.mdpi.com/2072-6694/13/19/4739

Similar Items